Selvigaltin (GB1211), an orally obtainable small molecule galectin-three inhibitor developed for a therapy for liver fibrosis and cirrhosis, was evaluated to assess the outcome of hepatic impairment on its pharmacokinetics and security to handle regulatory requirements. Table 4 Statistical evaluation of dose proportionality from the pharmacokinetic parameters of GB1211 next https://selvigaltin-oral-small-mo91245.blog-eye.com/39579628/the-smart-trick-of-selvigaltin-galectin-3-inhibitor-that-nobody-is-discussing